SIX MONTH OUTCOMES AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY PERSISTENCE AMONG COMMERCIALLY INSURED ADULTS WITHOUT DIABETES IN AN OBESITY CARE MANAGEMENT PROGRAM
Author(s)
Landon Z. Marshall, PharmD, PhD, Benjamin Urick, PharmD, PhD, Zach Lehman, BS, Todd Cooperman, BA, MBA, PharmD, Patrick Gleason, PharmD;
Prime Therapeutics, Eagan, MN, USA
Prime Therapeutics, Eagan, MN, USA
OBJECTIVES: Obesity is a complex, chronic disease requiring personalized, holistic care management. Glucagon-like peptide-1 receptor agonists (GLP-1) obesity pivotal trials included holistic care management. However, the impact of obesity care management programs in the real-world setting has been poorly explored. This study evaluated changes in weight and body mass index (BMI) and GLP-1 obesity treatment persistence among commercially insured adults without diabetes utilizing GLP-1 obesity treatment products after six months of enrollment in an obesity care management program.
METHODS: Prime Therapeutics’ obesity care management program and integrated medical and pharmacy claims data were used to identify members enrolled in an obesity care management program between 1/1/2025 and 6/30/2025. To be included in this study, members were required to initiate a weight loss GLP-1 product and remain enrolled for at least 180 days. Demographics, clinical characteristics, and persistence rates were summarized descriptively. Changes in weight and BMI among members with complete measurements were measured using paired t-tests. GLP-1 obesity treatment persistence was assessed after 180 days and defined as continuous GLP-1 therapy without a gap >60 days.
RESULTS: Among the 473 members with an obesity care management enrollment record, 72.5% (343) met full study inclusion; 79.0% were female, and mean age was 46.2 years. Mean baseline weight and BMI were 230.4 lbs and 37.2 kg/m2. Among members with complete clinical data [77.3% (265)], mean weight change was -22.5 lbs (95% CI: -20.4 to -24.6, p<.001) and mean BMI change was -3.6 kg/m2 (95% CI: -3.3 to -4.0, p<.001). At month six, 327 (95.3%) members remained on GLP-1 therapy, with 16 members discontinuing therapy.
CONCLUSIONS: For commercially insured adults, enrollment in an obesity care management program supports weight and BMI reductions and facilitates GLP-1 obesity treatment persistence. These findings highlight the role of personalized, holistic care management in the real-world setting to optimize obesity care.
METHODS: Prime Therapeutics’ obesity care management program and integrated medical and pharmacy claims data were used to identify members enrolled in an obesity care management program between 1/1/2025 and 6/30/2025. To be included in this study, members were required to initiate a weight loss GLP-1 product and remain enrolled for at least 180 days. Demographics, clinical characteristics, and persistence rates were summarized descriptively. Changes in weight and BMI among members with complete measurements were measured using paired t-tests. GLP-1 obesity treatment persistence was assessed after 180 days and defined as continuous GLP-1 therapy without a gap >60 days.
RESULTS: Among the 473 members with an obesity care management enrollment record, 72.5% (343) met full study inclusion; 79.0% were female, and mean age was 46.2 years. Mean baseline weight and BMI were 230.4 lbs and 37.2 kg/m2. Among members with complete clinical data [77.3% (265)], mean weight change was -22.5 lbs (95% CI: -20.4 to -24.6, p<.001) and mean BMI change was -3.6 kg/m2 (95% CI: -3.3 to -4.0, p<.001). At month six, 327 (95.3%) members remained on GLP-1 therapy, with 16 members discontinuing therapy.
CONCLUSIONS: For commercially insured adults, enrollment in an obesity care management program supports weight and BMI reductions and facilitates GLP-1 obesity treatment persistence. These findings highlight the role of personalized, holistic care management in the real-world setting to optimize obesity care.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO168
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity)